A randomized, placebo-controlled, double-dummy, four-way crossover design study to investigate the changes of fMRI BOLD [functional magnetic resonance imaging blood oxygenation level dependent] activation induced by emotional activation paradigms following single doses of GW876008 and lorazepam (comparator) in healthy subjects.

Trial Profile

A randomized, placebo-controlled, double-dummy, four-way crossover design study to investigate the changes of fMRI BOLD [functional magnetic resonance imaging blood oxygenation level dependent] activation induced by emotional activation paradigms following single doses of GW876008 and lorazepam (comparator) in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2010

At a glance

  • Drugs Emicerfont; Lorazepam
  • Indications Anxiety disorders; Depressive disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 Oct 2008 Actual start date changed from Jan 2007 to Mar 2007 as reported by Clinicaltrials.gov.
    • 01 Jun 2008 Status changed from recruiting to completed.
    • 17 Sep 2007 Status changed from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top